The content of this presentation does not constitute a promise or statement regarding the future performance of the Company. Certain information and conclusions contained herein are related to business prospects, estimate of the Company's operating and financial results and growth prospects.
This information is based on projections related to the Company's management expectations regarding the future of the business and considerations depend on market conditions, regulatory approval, industry performance, exchange rate fluctuations and other risks described in the Company's reports.
Certain percentages and other values included this document have been rounded to make its presentation easier and chart scales can have different proportions, also to make ease of viewing. Therefore, the numbers and graphs generated may not represent an arithmetic sum and may differ from those presented in financial statements.
This presentation does not constitute an offer or solicitation to purchase shares or any other real estate assets of the Company. The presentation or any information contained herein is not to be used on the basis of a contract or commitment.
The information contained herein is informative and should be understood as such.
2
Net Revenue and
Convidecia Vaccine
Private Capital
Gross Profit
increase
HIGHLIGHTS
OPERATING AND FINANCIAL
HIGHLIGHTS
Earnings Presentation
1Q22
Net Revenue
R$ Million
34,3
36,7
19,7
22,8
25,4
25,4
18,8
13,3
13,3
8,9
11,2
1Q20
2Q20
3Q20
4Q20
1Q21
2Q21
3Q21
4Q21
1Q22
1Q21
1Q22
The net revenue annual evolution of 91.1% in 1Q22 reflects the continuous evolution of the Company's portfolio and ramp-up. In comparison with 4Q21, the 11.6% increase mainly reflects the increase in Herzuma sales in the quarter
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
BIOMM SA published this content on 16 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2022 10:51:09 UTC.
Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Companyâs technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Companyâs technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Companyâs subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
BIOMM S.A. 
